

Product Data Sheet

Product Name: JMV 449
Cat. No.: GC17784

Chemical Properties

Cas. No. 139026-66-7

Chemical Name (R)-2-((2S,3R)-2-((S)-2-((R)-1-((R)-6-amino-2-(((R)-2,6-diaminohexyl)amino)hexanoyl)pyrrolidine-2-carboxamido)-3-(4-hydroxyphenyl)propanamido)-3-methylpentanamido)-4-methylpentanoic acid

SMILES O=C([C@@H](CCCCN)NC[C@@H](CCCCN)N1[C@@H](C(N[C@@H](C(N[C@@H](C(N[C@@H](C(O)=O)CC(C)C=O)[C@H](C)CC)=O)CC(C=C2)=CC=C2O)=O)CCC1


Formula $C_{38}H_{66}N_8O_7$ M.Wt 746.96

Solubility Soluble to 0.80 mg/ml in Water Storage Desiccate at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice. All other available size: ship with RT, or blue ice upon request.

Structure



Protocol

Cell experiment [1]:

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Cell lines	CHO-NTR cells (Chinese hamster ovary cells expressing neurotensin receptor cDNA)
Preparation Method	CHO-NTR cells were seeded at 5×10^3 cells per well in 24-well plates and grown for 48 hours, then treated with 3nM JMV 449 for 12 or 20 hours; living unstained cells were analyzed, cell division timing, and morphological classification (round, thin-long, oval) at multiple time points.
Reaction Conditions	3nM; 12h and 20h
Applications	JMV 449 retarded CHO-NTR cell division with delayed cell doubling time at 20 hours, and induced significant morphological changes with increased proportion of thin and long cells at 12 hours.
Animal experiment [2]:	
Animal models	Male C57BL/6 mice (10 months old)
Preparation Method	Overnight fasted (18h) mice received a single intraperitoneal injection of 25nmol/kg JMV 449 alone, or co-injected with 18mmol/kg glucose, or co-injected with 25nmol/kg (D-Ala2)GIP or 25nmol/kg exendin-4, or co-injected with 25nmol/kg (D-Ala2)GIP plus 2.5nmol/kg exendin-4; blood glucose and plasma insulin were measured at 0, 15, 30, 60 and 105min, and cumulative food intake was measured at 30min intervals for 180min.
Dosage form	25nmol/kg; i.p.; single injection

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

Applications	JMV 449 lowered blood glucose at 15 and 30min after glucose co-injection, increased 0-105min plasma insulin AUC, reduced cumulative food intake in overnight fasted mice, and enhanced the glucose-lowering effect of (D-Ala ²)GIP and exendin-4 and the appetite-suppressing effect of 2.5nmol/kg exendin-4.
References: [1] Xu-Van Opstal WY, Ranger C, Lejeune O, et al. Automated image analyzing system for the quantitative study of living cells in culture. Microsc Res Tech. 1994;28(5):440-447. [2] Craig SL, Gault VA, Shiels CE, et al. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control. BBA Gen Subj. 2021;1865:129917.	

Background

JMV 449 is a potent and long-acting neurotensin receptor (NTR) agonist peptide. JMV 449 inhibits [¹²⁵I]-neurotensin binding to newborn mouse brain (IC₅₀=0.15nM) and contracts guinea pig ileum (EC₅₀=1.9nM). JMV 449 activates central and peripheral neurotensin receptors to induce sustained hypothermia, central analgesia and neuroprotection. JMV 449 modulates dopaminergic pathways, affects gastrointestinal motility and insulin secretion. JMV 449 can be used for related research on psychiatric disorders, pain, cerebral ischemia, metabolic disorders and tumors such as liver cancer and pancreatic cancer^[1-4].

In vitro, treatment of CHO-NTR cells with 3nM JMV 449 for 12-20 hours induced significant morphological changes, increased the proportion of elongated cells, and delayed cell division^[5]. Treatment of CHP 212 and N1E-115 cells with 1μM JMV 449 for 5-72 hours activated tyrosine hydroxylase gene expression and mobilized intracellular Ca²⁺^[6]. Treatment of CHP212 cells with 1μM JMV 449 for 5-72 hours elevated tyrosine hydroxylase protein levels and enhanced tyrosine hydroxylase transcriptional activity^[7].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In vivo, intraperitoneal injection of 25nmol/kg JMV 449 combined with 18mmol/kg glucose in male C57BL/6 mice fasted for 18 hours lowered blood glucose concentration and reduced cumulative food intake^[8]. Intracerebroventricular injection of 60-240pmol JMV 449 in Swiss mice decreased colonic temperature, produced a dose-dependent hypothermic effect, prolonged tail-flick latency and produced an analgesic effect^[9]. Intracerebroventricular injection of 0.6nmol JMV 449 in NMRI mice 10 minutes after permanent distal middle cerebral artery occlusion reduced core body temperature and decreased infarct volume^[10].

References:

- [1] Peltonen I, Myöhänen TT, Männistö PT. Different interactions of prolyl oligopeptidase and neurotensin in dopaminergic function of the rat nigrostriatal and mesolimbic pathways. *Neurochem Res.* 2012 Sep;37(9):2033-41.
- [2] Camby I, Salmon I, Bourdel E, et al. Neurotensin-mediated effects on astrocytic tumor cell proliferation. *Neuropeptides.* 1996 Apr;30(2):133-9.
- [3] Borroto-Escuela DO, Ravani A, Tarakanov AO, et al. Dopamine D2 receptor signaling dynamics of dopamine D2-neurotensin 1 receptor heteromers. *Biochem Biophys Res Commun.* 2013 May 24;435(1):140-6.
- [4] Souazé F, Rostène W, Forgez P. Neurotensin agonist induces differential regulation of neurotensin receptor mRNA. Identification of distinct transcriptional and post-transcriptional mechanisms. *J Biol Chem.* 1997 Apr 11;272(15):10087-94.
- [5] Xu-Van Opstal WY, Ranger C, Lejeune O, et al. Automated image analyzing system for the quantitative study of living cells in culture. *Microsc Res Tech.* 1994;28(5):440-447.
- [6] Najimi M, Souazé F, Méndez M, et al. Activation of receptor gene transcription is required to maintain cell sensitization after agonist exposure: study on neurotensin receptor. *J Biol Chem.* 1998 Aug 21;273(34):21634-21641.
- [7] Najimi M, Hermans E, Rostène W, et al. Transcriptional Regulation of the Tyrosine Hydroxylase Gene by Neurotensin in Human Neuroblastoma CHP212 Cells. *Metab Brain Dis.* 2001 Dec;16(3-4):165-174.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

[8] Craig SL, Gault VA, Shiels CE, et al. Comparison of independent and combined effects of the neurotensin receptor agonist, JMV-449, and incretin mimetics on pancreatic islet function, glucose homeostasis and appetite control. *BBA Gen Subj.* 2021;1865:129917.

[9] Dubuc I, Costentin J, Doulut S, et al. JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. *Eur J Pharmacol.* 1992 Jul 21;219(2):327-329.

[10] Torup L, Borsdal J, Sager T. Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. *Neurosci Lett.* 2003 Sep 11;351(3):173-176.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA